# Study Guide: Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer (ASCO Guideline Update)

This study guide provides a comprehensive overview of the updated clinical practice guidelines regarding the use of neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) for patients with stage III-IV epithelial ovarian cancer (EOC).

---

## Key Concepts and Core Recommendations

### 1. Initial Assessment and Diagnostics
All patients with suspected stage III or IV EOC must undergo a specialized evaluation before therapy begins. The primary goal is to determine the feasibility of surgical resection and identify the molecular profile of the tumor.

*   **Multidisciplinary Evaluation:** Every patient must be evaluated by a gynecologic oncologist.
*   **Imaging Standards:** Primary clinical evaluation should include:
    *   Cancer antigen 125 (CA-125) testing.
    *   CT of the abdomen and pelvis (with oral and intravenous contrast).
    *   Chest imaging (CT is preferred).
*   **Supplemental Tools:** Laparoscopy is highly reliable (90% accuracy) in predicting the feasibility of complete resection. Other tools include diffusion-weighted MRI, FDG-PET scans, and ultrasound.
*   **Genetic Testing:** Germline and somatic testing for *BRCA1* and *BRCA2* and other susceptibility genes should be offered to all patients at the time of diagnosis. Testing should also include measures of homologous recombination deficiency (HRD).

### 2. Primary Cytoreductive Surgery (PCS) vs. Neoadjuvant Chemotherapy (NACT)
The choice between immediate surgery and chemotherapy followed by surgery is a critical clinical decision based on patient fitness and disease burden.

| Treatment Approach | Candidate Profile | Primary Goal |
| :--- | :--- | :--- |
| **Primary Cytoreductive Surgery (PCS)** | Patients fit for surgery with a high likelihood of achieving complete cytoreduction (no gross residual disease) with acceptable morbidity. | Maximal tumor debulking prior to the initiation of systemic therapy. |
| **Neoadjuvant Chemotherapy (NACT)** | Patients fit for surgery but deemed unlikely to achieve complete cytoreduction, or patients with a high perioperative risk profile (e.g., advanced age, frailty, poor nutritional status). | Reduction of tumor volume to increase the likelihood of optimal cytoreduction during subsequent surgery and reduce surgical complexity. |

### 3. Requirements for NACT Delivery
Before NACT can be administered, clinicians must ensure an accurate diagnosis to avoid treating non-ovarian malignancies.

*   **Histologic Confirmation:** A core tissue biopsy is strongly preferred over fine-needle aspiration.
*   **Alternative Diagnostics:** In exceptional cases where a biopsy is impossible, a combination of cytologic evaluation and a serum CA-125 to CEA ratio >25 may be used to exclude non-gynecologic cancers.
*   **Endometrial Sampling:** Should be considered when endometrial cancer is suspected as the primary etiology.

### 4. Treatment Regimens and Timing
*   **Preferred Regimen:** A platinum-taxane doublet (e.g., carboplatin and paclitaxel) is the standard for NACT.
*   **Interval Cytoreductive Surgery (ICS):** Should ideally be performed after no more than four cycles of NACT for patients showing a clinical response or stable disease.
*   **Total Cycle Count:** A total treatment plan of six cycles (NACT cycles plus post-ICS cycles) is generally recommended.
*   **HIPEC:** Hyperthermic intraperitoneal chemotherapy (cisplatin 75–100 mg/m²) may be offered during ICS for patients with FIGO stage III disease who have a good performance status and adequate renal function.

### 5. Maintenance and Progression
*   **Maintenance Therapy:** Patients should be offered FDA-approved options based on their molecular profile. This includes PARP inhibitors (olaparib, niraparib) for those with *BRCA* mutations or HRD-positive status, and bevacizumab.
*   **Progression on NACT:** If disease progresses during NACT, clinicians should reconfirm the diagnosis via tissue biopsy. Management options include alternative chemotherapy, clinical trials, or a transition to end-of-life care. Surgery is generally discouraged in these cases unless required for palliation (e.g., bowel obstruction).

---

## Short-Answer Practice Questions

1.  **Which medical specialist must evaluate a patient with suspected advanced EOC before treatment begins?**
    *   *Answer:* A gynecologic oncologist.
2.  **What is the "standard of care" definition for optimal debulking in PCS?**
    *   *Answer:* Achieving complete cytoreduction, meaning no gross residual tumor remains.
3.  **Why is a core tissue biopsy preferred over fine-needle aspiration before starting NACT?**
    *   *Answer:* Core biopsies provide adequate sampling to distinguish between borderline and invasive cancer and ensure enough material for genetic and somatic tumor testing.
4.  **What specific timing is recommended for Interval Cytoreductive Surgery (ICS) during a NACT regimen?**
    *   *Answer:* ICS should be performed after $\le$ 4 cycles of chemotherapy for patients with a response or stable disease.
5.  **Under what clinical conditions may HIPEC be offered?**
    *   *Answer:* It may be offered during ICS to patients with FIGO stage III disease who have good performance status, adequate renal function, and were treated with NACT.
6.  **What are the two primary reasons a patient might be directed toward NACT rather than PCS?**
    *   *Answer:* 1) A high likelihood that complete cytoreduction cannot be achieved by the surgeon, and 2) A high perioperative risk profile (frailty, comorbidities, etc.).
7.  **What biomarker ratio is used to help confirm an ovarian primary when a biopsy cannot be performed?**
    *   *Answer:* A CA-125 to CEA ratio >25.
8.  **According to the guidelines, when should genetic testing (germline and somatic) occur?**
    *   *Answer:* At the time of diagnosis or as soon as feasibly possible.

---

## Essay Prompts for Deeper Exploration

1.  **The Evolution of Upfront Treatment:** Analyze the shift in treatment practices in the United States from Primary Cytoreductive Surgery (PCS) to Neoadjuvant Chemotherapy (NACT). Discuss the evidence regarding survival outcomes and perioperative complications as presented in the randomized controlled trials (EORTC 55971, CHORUS, SCORPION, and JCOG0602).
2.  **Multidisciplinary Decision-Making:** Explain the factors a clinical team must consider when individualizing the decision between PCS and NACT. How do tumor biology, imaging scores (e.g., PCI), and patient performance status influence the likelihood of surgical success and long-term survival?
3.  **Health Equity and Access:** Based on the guideline's discussion of social determinants of health, examine the documented disparities in ovarian cancer care. Discuss how factors like race, geographical location (rural vs. urban), and insurance type impact the likelihood of receiving a gynecologic oncology consultation and adhering to standard-of-care guidelines.
4.  **The Role of Genomic and Somatic Testing:** Evaluate the importance of identifying *BRCA* mutations and Homologous Recombination Deficiency (HRD) early in the diagnostic process. How does this molecular information influence maintenance therapy decisions and the long-term management of the patient and their family?

---

## Glossary of Important Terms

*   **CA-125 (Cancer Antigen 125):** A biomarker used in the initial evaluation and monitoring of response to chemotherapy in ovarian cancer.
*   **CEA (Carcinoembryonic Antigen):** A protein used in conjunction with CA-125 to help differentiate between gynecologic and non-gynecologic (e.g., gastrointestinal) cancers.
*   **Complete Cytoreduction (R0):** A surgical outcome where no macroscopic (visible) residual tumor remains after debulking.
*   **EOC (Epithelial Ovarian Cancer):** A category of cancer that includes fallopian tube and primary peritoneal cancers.
*   **FIGO Stage:** The International Federation of Gynecology and Obstetrics staging system; stage III and IV represent advanced-stage disease.
*   **HIPEC (Hyperthermic Intraperitoneal Chemotherapy):** The administration of heated chemotherapy directly into the abdominal cavity during surgery.
*   **HRD (Homologous Recombination Deficiency):** A molecular state that makes tumor cells more sensitive to certain treatments, such as PARP inhibitors.
*   **ICS (Interval Cytoreductive Surgery):** Surgery performed after several cycles of neoadjuvant chemotherapy to debulk the remaining tumor.
*   **NACT (Neoadjuvant Chemotherapy):** Systemic chemotherapy administered prior to surgical intervention to reduce tumor burden.
*   **PARPi (Poly(ADP-ribose) Polymerase Inhibitors):** A class of maintenance drugs (e.g., olaparib, niraparib) used to treat EOC, particularly in patients with *BRCA* mutations or HRD.
*   **PCI (Peritoneal Cancer Index):** A scoring system used (often during laparoscopy) to quantify the extent of cancer throughout the peritoneal cavity.
*   **PCS (Primary Cytoreductive Surgery):** The initial surgical effort to debulk the tumor before any chemotherapy is administered.
*   **Platinum-Taxane Doublet:** The standard chemotherapy combination (typically carboplatin and paclitaxel) used for both NACT and adjuvant treatment of EOC.